Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Herbert R. Henney"'
Autor:
Charles Oh, Aaron Ellenbogen, Herbert R. Henney, Ping Zhao, Deena M. Kegler-Ebo, Beth Safirstein
Publikováno v:
Clinical therapeutics. 42(6)
Purpose Levodopa (LD) is the most effective oral pharmacotherapy for the management of motor symptoms in Parkinson's disease. However, LD use is complicated by a progressive shortening of the duration of efficacy of a dose, resulting in episodes of i
Autor:
Angela Applebee, Myla D. Goldman, Gabriel Pardo, Michele Mass, Robert Yapundich, Enrique Carrazana, Francois Bethoux, Herbert R. Henney, Andrew R. Blight, George J. Hutton, Michael Klingler
Publikováno v:
International Journal of MS Care. 17:138-145
Background: Dalfampridine extended-release (ER) tablets, 10 mg twice daily, have been shown to improve walking in people with multiple sclerosis. We evaluated the safety and efficacy of dalfampridine-ER 5 mg compared with 10 mg. Methods: Patients wer
Autor:
Adrian L. Rabinowicz, Herbert R Henney rd, Clayton W. Snell, Daniel Kantor, Michael B. Chancellor
Publikováno v:
Postgraduate Medicine. 127:218-222
Urinary tract infections (UTIs) were reported frequently with dalfampridine extended-release (dalfampridine-ER) 10 mg relative to placebo in previous multiple sclerosis (MS) studies. The objective of this study was to determine whether dalfampridine-
Autor:
Randall T Schapiro, Extension Study Investigators, Francois Bethoux, Andrew D. Goodman, Theodore R Brown, Andrew R. Blight, Ronald A. Cohen, Lawrence Marinucci, Herbert R. Henney
Publikováno v:
Multiple Sclerosis (Houndmills, Basingstoke, England)
Background: In Phase 3 double-blind trials (MS-F203 and MS-F204), dalfampridine extended release tablets 10 mg twice daily (dalfampridine-ER; prolonged-release fampridine in Europe; fampridine modified or sustained release elsewhere) improved walking
Publikováno v:
Epilepsy Research. 108:1204-1211
Diazepam rectal gel (RG) is currently the only approved rescue therapy for outpatient management of seizure clusters in the United States. There is an unmet medical need for an alternative rescue therapy for seizure clusters that is effective, and mo
Autor:
David Squillacote, Gary Bream, Michael R. Sperling, Adrian L. Rabinowicz, Enrique Carrazana, Hussam Seif Eddeine, Kevin F. Haas, Gregory L. Krauss, Herbert R. Henney
Publikováno v:
Epilepsia. 55:1544-1550
Summary Objective To determine the feasibility of administering a diazepam nasal spray formulation (diazepam-NS) to adults with epilepsy during a generalized tonic–clonic seizure or in the postictal period following a tonic–clonic or other seizur
Autor:
Angela Lee, Emil Samara, Peter Winkle, Herbert R. Henney, Susan L. Way, Patricia Pardo, Andrew R. Blight, Eppie Brown
Publikováno v:
Journal of Clinical Pharmacology
Dalfampridine extended release tablets (D-ER; prolonged-release fampridine in Europe) are available to improve walking in patients with multiple sclerosis (MS). D-ER is mainly renally eliminated; the approved 10-mg twice daily dose is contraindicated
Publikováno v:
Current Medical Research and Opinion. 29:1637-1645
Using data pooled from several studies of dalfampridine extended release (ER), a population pharmacokinetic model was developed for the purposes of characterizing the population pharmacokinetics and pharmacodynamics of dalfampridine-ER with respect t
Publikováno v:
Current Medical Research and Opinion. 29:1627-1636
In January 2010, dalfampridine extended release tablets (dalfampridine-ER [Ampyra *]; prolonged-, modified- or sustained-release fampridine [Fampyra †] in some countries), 10 mg to be administered twice daily approximately 12 hours apart, were appr
Autor:
Gabriel Pardo, Adrian L. Rabinowicz, Cecilie Fjeldstad, Herbert R. Henney, Michael Klingler, Gustavo Suarez
Publikováno v:
International journal of MS care. 17(6)
Background: Dalfampridine extended release (ER) improves walking in people with multiple sclerosis (MS), as demonstrated by walking speed improvement. This exploratory study evaluated treatment effects of dalfampridine-ER on gait, balance, and walkin